Overview

Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of hepatic impairment on the single dose pharmacokinetics of BMS-790052.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb